Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Low doses of amyloid beta protein in healthy brains can cause Alzheimer's disease, say scientists

While too much amyloid beta protein in the brain is linked to the development of Alzheimer's disease, not enough of the protein in healthy brains can cause learning problems and forgetfulness, Saint Louis University scientists have found.

10 Nov 2009

Alzheimer's disease research draws national attention

Research that is targeting the early diagnosis of Alzheimer disease has drawn national attention to the work of Michael Seidenberg, PhD, a faculty member at Rosalind Franklin University of Medicine and Science.

10 Nov 2009

Children with autism may have lower quality handwriting, says study

Children with autism may have lower quality handwriting and trouble forming letters compared to children without autism, according to a study published in the November 10, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

9 Nov 2009

New micronail chip to enable electronics and biological cells communicate with each other

IMEC presents a unique microchip with microscopic nail structures that enable close communication between the electronics and biological cells. The new chip is a mass-producible, easy-to-use tool in electrophysiology research, for example for fundamental research on the functioning and dysfunctioning of the brain. Each micronail structure serves as a close contact-point for one cell, and contains an electrode that can very accurately record and trigger in real-time the electrical activity of an individual electrogenic cell in a network.

9 Nov 2009

TNS files Provisional Use Patent application on the ability of a natural organic mushroom formula

Total Nutraceutical Solutions, Inc. (TNS), announced that it has filed a Provisional Use Patent application on the ability of a proprietary natural organic mushroom formula to control oxidative stress.

9 Nov 2009

Seminar highlights the importance of chronic health issues

With 125 million Americans challenged by at least one chronic illness and 22% of that number facing life with two or more chronic illnesses, early, smart estate and financial planning can make the difference between maximizing control over your life or falling victim to its exigencies.

7 Nov 2009

Women with high levels of homocysteine more likely to suffer from Alzheimer's disease

Middle-aged women with high levels of a specific amino acid in their blood are twice as likely to suffer from Alzheimer's many years later, reveals a thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden. This discovery this could lead to a new and simple way of determining who is at risk long before there are any signs of the illness.

6 Nov 2009

Landmark meeting discusses goal of detecting Alzheimer disease before symptoms appear

This past October, 214 researchers from the U.S., Europe, and Australia, as well as representatives of families with aggressive genetic forms of Alzheimer disease (AD), met at Washington University, St. Louis, Missouri, to devote two intense days of talks and discussion to their goal of detecting this disease before symptoms appear. By a growing consensus, defining the "silent" phase of AD has become the field's central challenge if it is to modernize drug testing and lay the groundwork for AD prevention trials.

6 Nov 2009

Researchers develop new molecular tools to investigate Alzheimer's disease

One of the many mysteries of Alzheimer's disease is how protein-like snippets called amyloid-beta peptides, which clump together to form plaques in the brain, may cause cell death, leading to the disease's devastating symptoms of memory loss and other mental difficulties.

5 Nov 2009

People with MS who relapse within first five years of onset have more severe disability: Study

People with multiple sclerosis (MS) who have relapses within the first five years of onset appear to have more severe disability in the short term compared to people who do not have an early relapse, according to a new study published in the November 4, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology. The study is one of the first to examine how MS relapses affect people during different time periods of the disease.

5 Nov 2009

Nano-size capsule that boosts the body's uptake of curcumin being developed

Scientists are reporting development of a nano-size capsule that boosts the body's uptake of curcumin, an ingredient in yellow curry now being evaluated in clinical trials for treatment of several diseases. Their study is in ACS' Journal of Agricultural and Food Chemistry, a bi-weekly publication.

5 Nov 2009

EFOF's initative to raise epilepsy awareness

Each year, some 50,000 Americans die from seizures and related causes, triggering more deaths annually than breast cancer. The Epilepsy Foundation of Florida (EFOF) is working to educate the public about this condition during November, Epilepsy Awareness Month.

4 Nov 2009

Safeguard Scientifics reports financial results for the third quarter of 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that third quarter consolidated net loss from continuing operations attributable to Safeguard common shareholders was $11.6 million, or $0.57 per share, compared with a net loss of $4.1 million, or $0.20 per share, in the same period of 2008.

4 Nov 2009

Canadian patients have less access to the latest medicines, says report

Canadian patients have less access to the latest medicines when compared to the world's developed countries, concludes a comprehensive new report released today. The Report shows Canada ranks 20th out of 25 OECD countries in public reimbursement of new drug therapies. Canada's grade of 56% is comparable with Iceland, Slovakia and Turkey.

4 Nov 2009

Pfizer and Medivation initiate dimebon trials in patients with Alzheimer’s disease

Pfizer Inc and Medivation, Inc. today announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer’s disease (AD).

4 Nov 2009

Arrowhead Research updates its shareholders

Arrowhead Research Corporation’s (NASDAQ: ARWR) President and Chief Executive Officer today issued the following letter to the Company’s shareholders.

3 Nov 2009

New study to assess preventative brain radiation therapy for lung cancer patients

A new study is taking a closer look at the benefits versus risks for lung cancer patients to undergo preventative brain radiation therapy as a means to stop cancer from spreading to the brain.

3 Nov 2009

High blood pressure and an innate pro-inflammatory cytokine response contribute to Alzheimer's disease

High blood pressure, evidence of arterial disease and markers of inflammation in the blood in middle age appear more common in individuals whose parents have Alzheimer's disease than in individuals without a parental history of the condition, according to a report in the November issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

3 Nov 2009

ExonHit Therapeutics to take part in MAPT study for early detection of Alzheimer’s disease

ExonHit Therapeutics (Paris:ALEHT) together with Toulouse University Hospital and l’Institut de Recherche Pierre Fabre (IRPF) will participate in the Multidomain Alzheimer Preventive Trial (MAPT). The study’s main objective is to assess the efficacy of a multidomain (nutrition, physical exercise, cognitive stimulation) intervention associated with an omega-3 treatment in preventing the decline of cognitive functions in aged and frail individuals.

2 Nov 2009

Molecular imaging pinpoints inflammation in the brains of schizophrenics and migraine sufferers

Inflammatory response of brain cells-as indicated by a molecular imaging technique-could tell researchers more about why certain neurologic disorders, such as migraine headaches and psychosis in schizophrenic patients, occur and provide insight into how to best treat them, according to two studies published in the November issue of the Journal of Nuclear Medicine.

31 Oct 2009

Alzheimer's Disease News and Research

Further Reading

Low doses of amyloid beta protein in healthy brains can cause Alzheimer's disease, say scientists

Alzheimer's disease research draws national attention

Children with autism may have lower quality handwriting, says study

New micronail chip to enable electronics and biological cells communicate with each other

TNS files Provisional Use Patent application on the ability of a natural organic mushroom formula

Seminar highlights the importance of chronic health issues

Women with high levels of homocysteine more likely to suffer from Alzheimer's disease

Landmark meeting discusses goal of detecting Alzheimer disease before symptoms appear

Researchers develop new molecular tools to investigate Alzheimer's disease

People with MS who relapse within first five years of onset have more severe disability: Study

Nano-size capsule that boosts the body's uptake of curcumin being developed

EFOF's initative to raise epilepsy awareness

Safeguard Scientifics reports financial results for the third quarter of 2009

Canadian patients have less access to the latest medicines, says report

Pfizer and Medivation initiate dimebon trials in patients with Alzheimer’s disease

Arrowhead Research updates its shareholders

New study to assess preventative brain radiation therapy for lung cancer patients

High blood pressure and an innate pro-inflammatory cytokine response contribute to Alzheimer's disease

ExonHit Therapeutics to take part in MAPT study for early detection of Alzheimer’s disease

Molecular imaging pinpoints inflammation in the brains of schizophrenics and migraine sufferers

Aneuro: A Year of Neuroscience in Review eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News